Microcephalic osteodysplastic primordial dwarfism type II (MOPD II, MIM 210720) and Seckel syndrome (SCKL, MIM 210600) belong to the primordial dwarfism group characterized by intrauterine growth retardation, severe proportionate short stature and marked microcephaly. MOPD II is distinct from SCKL by more severe growth retardation, radiological abnormalities and absent or mild mental retardation. Seckel syndrome is associated with defective ATR-dependent DNA damage signalling.
INTRODUCTION
Among the primordial dwarfisms, microcephalic osteodysplastic primordial dwarfism type II (MOPD II, MIM 210720) and Seckel syndrome (SCKL, MIM 210600) are both characterized by intrauterine growth retardation, severe proportionate short stature and microcephaly [1, 2] . MOPDII is distinct from SCKL by the severity of the growth retardation, the presence of skeleton abnormalities and the mild/ absent mental retardation [3] . SCKL is a genetically heterogeneous condition associated with defective ATR-dependent DNA damage signalling [4] . The only reported genetic defect so far is a hypomorphic mutation in the ATR gene (Sckl1, 3q22.1-q24) [5] . In 2008, mutations in the pericentrin gene (PCNT) have been identified in 28 patients, including 3 patients with SCKL [6] and 25 with MOPDII [7] .This gene encodes a centrosomal protein, which acts both at structural and regulatory levels. First, pericentrin recruits several structural centrosomal proteins, particularly gamma tubulin ring complex which initiates microtubular nucleation and spindle organization [8, 9, 10, 11] .
Second, it plays a role in cell cycle regulation through its interaction with the ATR pathway [6] . All mutations identified so far lead to premature translation termination and are responsible for pericentrin loss of function as demonstrated in PCNT-mutated cell lines issued from patients with SCKL or MOPDII.
To further define the clinical spectrum of patients with PCNT mutations, we analyzed PCNT in 24 families diagnosed either with SCKL or with MOPD II, including 18 consanguineous families and 6 cases from unrelated parents.
PATIENTS AND METHODS

Patients
Criteria for inclusion in the study were: Diagnostic assessment was performed for all patients by their clinicians ( Table 1) .
Seven of these families were previously clinically reported, by Faivre et al [12] (families 1,3,7, 8, 11 and 12) and Verloes et al [13] (family 19). Written informed consent was obtained from all subjects included in this study.
Microsatellites marker analysis
In all consanguineous families, microsatellites analysis of the PCNT locus was first performed and PCNT was sequenced only in compatible cases. The PCNT sequence analysis was performed in all cases from unrelated parents. Blood samples were obtained with informed consent from affected children, parents and unaffected siblings. Genomic DNA was extracted using Nucleospin® Blood XL kit (Macherey-Nagel). We established lymphoblastoid cell lines by EBV transformation and we performed a primary skin fibroblasts culture. Genotyping was performed using 4 flanking (D21S1903, D21S1897, D21SpolyATT, D21S1446) and one intragenic-PCNT (PCNT-IG) microsatellite markers in all consanguineous families and non-consanguineous families with at least two siblings.
Mutation analysis
PCNT exon and flanking intron sequences were amplified from patient DNA by PCR using 49 couples of primers designed with the Primer 3 software (Sequence of primers available on request). Sequencing reactions were performed on both strands using the BigDye Terminator Cycle Sequencing Kit v3.1 (Applied Biosystems, Foster City, California)
according to the manufacturer's instructions.
Functional consequences of c.3840G>C( p.Q1280H) mutation
RNA was extracted from cultured fibroblasts and cDNA was synthetized using primers designed to overlap 2 consecutive exons (Sequence of primers: JUNCTION17/18-5':
CCTGTCCCACAGCGAAAGAG; JUNCTION18/19-5': ACAGCTCCGGCGCTGGAG; JUNCTION20/21-3': GGGTACCCTGAGTCTTGTGCAGC). RT-PCR products were expected to span exons 18 to 20 and exons 19 to 20. GAPDH expression was used as positive controls.
RESULTS
Genotyping analysis showed that 9/18 consanguineous families (4/13 SCKL and 5/5 MOPDII) were compatible with linkage to the PCNT locus.
The PCNT sequence analysis performed in these 9 consanguineous families and in 6 additional cases (from unrelated parents) allowed the identification of 13 distinct mutations in 13 patients ( Among the 13 patients, 5 were clinically diagnosed as SCKL (patients12-16) and 8
were diagnosed as MOPDII (patients 17-24, Table 1 ). The identification of PCNT mutations in 5 SCKL and 8 MOPDII patients prompted us to re-analyze the clinical features of all the patients with PCNT mutations and compare them to SCKL patients without mutation. We first observed that the five SCKL patients with PCNT mutations (families 12-16) presented a more severe growth retardation than the SCKL patients without PCNT mutation (-6 to -8 SD versus -4 to -5 SD), but less severe than the MOPDII patients with PCNT mutation (-7 to -13 SD).
For two of them, the adult height is 120 cm and 140 cm respectively ( 
DISCUSSION
We report here the identification of 13 distinct mutations in 8 MOPDII and 5 SCKL patients. As previously reported by Griffith [6] and Rauch [7] , mutations are distributed throughout the gene. We did not find any recurrent mutations in our series. However, the c.3109G>T mutation (exon 15) was previously reported by Rauch et al in a patient also originating from Turkey (patient 1). In one patient (patient 22), one mutation only was detected by direct sequencing but unfortunately RNA was not available. This might be due to the limit of our screening and a partial deletion of PCNT gene cannot be excluded. Our study provides also the first example of a "missense" mutation (c.3840G>C) but we demonstrated that this mutation impairs exon 19 splicing, leading to premature termination of translation.
We conclude, as previously suggested, that all identified mutations are loss of function mutations.
We identified PCNT mutations in all MOPDII cases, confirming the genetic homogeneity of this disorder. Moreover, the retrospective analysis of the 5 SCKL patients with PCNT mutation also suggests that they all belong to the MOPDII spectrum. However, they were diagnosed as SCKL, based on the absence of severe skeletal manifestations and on their final stature >110 cm, which usually excludes the diagnosis of MOPDII [3] . Our study also supports that SCKL spectrum is heterogeneous and suffers from variable definition in the literature and from clinicians in practice. Indeed, Seckel syndrome has often been used as a generic term used for primordial dwarfism, without more specific diagnosis. Recently, D'Angelo and Di Bartolomeo reported two cases of SCKL with intracranial anomalies, suggestive of MOPDII diagnosis [16, 17] . Similarly, SCKL patients with bone dysplasia suggestive of MOPDII have been reported [18, 19] . From our study, we suggest that MOPDII spectrum is wider than previously defined. However, in all patients with PCNT mutations we have consistently observed 1) distinct facial features 2) growth retardation <-5SD and We also observed in two patients with PCNT mutation a liver involvement varying in severity from cytolysis to cirrhosis, with the same histological features than those described in the literature for patients with MOPDI diagnosis, consisting in ductular cholestasis, inflammatory infiltrate, and giant multinucleate hepatocytes. Although theses findings are not specific, they may suggest the existence of biliar epithelium anomalies in MOPDII spectrum [20] .
While this study further demonstrates that MOPDII is caused by PCNT mutations, the pathogenic mechanisms underlying the clinical features observed in these patients remain unclear [21] . First, microcephaly could be related to structural centrosomal abnormalities similar to those observed in primary microcephaly [22] . Second, defect in ATR-dependent DNA damage signalling has been demonstrated in other conditions characterized by short stature and microcephaly and may thereby also account for short stature observed in MOPDII cases [23, 24] . Other specific clinical features like vessels anomalies, generalized bone dysplasia and hepatitis remain unexplained so far, since they have not described in patients with ATR mutations or other centrosomal genes such as ASPM.
Finally, O'Driscoll and collaborators suggested that the ATR signalling pathway was unusually sensitive to haploinsufficiency and established a correlation between ATR-pathway dysfunction and growth retardation [23] . Similarly, Rauch et al reported a significant reduction of the mean height of heterozygous MOPDII parents [7] . We did not observe such a reduction in the mean of parental heights (ranging from -1 to +2 SD) but ethnical variability of growth charts may interfere with parental height analysis.
In conclusion, we identified 13 PCNT loss of function mutations in 13 patients who all presented diagnostic criteria for MOPDII. However, we observed a wider variability in the severity of the short stature and skeletal manifestations than previously admitted, modifying the MOPDII clinical spectrum. The distinction between SCKL and MOPDII appears to be crucial for the appropriate management, keeping in mind the risk of vascular anomalies in MOPDII.
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